Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) will likely be releasing its Q3 2026 results before the market opens on Wednesday, November 18th. Analysts expect the company to post earnings of ($1.24) per share and revenue of $1.01 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 7:00 AM ET.
Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.24) by ($0.41). The business had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $10.00 million. On average, analysts expect Zenas BioPharma to post ($6.23) EPS for the current fiscal year and ($4.99) EPS for the next fiscal year.
Zenas BioPharma Stock Performance
ZBIO stock opened at $27.93 on Tuesday. The company has a fifty day moving average price of $28.48 and a 200-day moving average price of $25.38. Zenas BioPharma has a 52-week low of $13.50 and a 52-week high of $44.60. The company has a quick ratio of 9.93, a current ratio of 9.42 and a debt-to-equity ratio of 1.88.
Analysts Set New Price Targets
Several analysts recently weighed in on the stock. Morgan Stanley assumed coverage on shares of Zenas BioPharma in a research note on Tuesday, October 20th. They issued an “equal weight” rating and a $32.00 price objective on the stock. Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, October 28th. HC Wainwright reaffirmed a “buy” rating and set a $44.00 target price on shares of Zenas BioPharma in a report on Tuesday, October 13th. Guggenheim reiterated a “buy” rating and issued a $55.00 price target on shares of Zenas BioPharma in a research report on Wednesday, September 30th. Finally, Wedbush reiterated an “outperform” rating and issued a $45.00 price target on shares of Zenas BioPharma in a research report on Wednesday, September 30th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $46.71.
Get Our Latest Stock Analysis on Zenas BioPharma
About Zenas BioPharma
Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Founded in 2019 and based in Waltham, Massachusetts, the company describes itself as a global biopharmaceutical business. Its lead investigational medicine, obexelimab, is a bifunctional antibody designed to bind CD19 and FcγRIIb and inhibit B-cell activity. Zenas is developing the drug for autoimmune conditions, including IgG4-related disease; it has not been approved for commercial use.
Read More
- Five stocks we like better than Zenas BioPharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Zenas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
